Dawn of a new era in olfactory regeneration: Pediatric stem cell therapy enters the era of long-term validation

Several human studies show positive signals, while research methods and sample sizes continue to develop.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

A recently published prospective study marks a breakthrough for congenital olfactory disorders in children. The study provides the first long-term, three-year follow-up data, robustly demonstrating the durable efficacy and safety of autologous nasal epithelial stem cell transplantation. This work reveals immense therapeutic potential for a condition traditionally considered untreatable. However, this milestone achievement also presents new challenges. To translate this pioneering therapy from a single-center success to a global standard, multicenter, controlled clinical trials must be initiated immediately. Only through rigorous validation can we ensure its widespread adoption and ultimately bring hope to millions of children worldwide.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.